The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anupam Rama - J.P. Morgan - Analyst
: I just want to remind folks there are three ways to ask a question. There is the old school way where you can raise your hand and I'll call on you.
There's the -- you can send a question in the question portal or you can just email me and Barry can read my email.
Question: Anupam Rama - J.P. Morgan - Analyst
: So Barry, I know you can't comment too much on the headlines that we saw on Friday, but maybe if I could ask what would be your strategic
objectives in this type of profit process?
Question: Anupam Rama - J.P. Morgan - Analyst
: I want to dig in a little bit on ZURZUVAE. Can you help us understand what pull through you've seen from sort of the sales force expansion particularly
I think there was a focus on the OB/GYN segment.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 15, 2025 / 4:15PM, SAGE.OQ - SAGE Therapeutics Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - J.P. Morgan - Analyst
: And what are you seeing in terms of new prescribers for the product and versus what seeing death with repeat prescribers.
Question: Anupam Rama - J.P. Morgan - Analyst
: Questions from the audience. We've got a question in the portal here, which is does your sales force sort also think about reaching out to pediatricians?
Most moms have one postpartum event with their OB/GYNs. However, they will see their pediatricians at least 1 month to 3 months over a 12
month period. What does your market research? Tell you about the percent of moms who develop PPD within the first week, first six weeks versus
sometime after?
Question: Anupam Rama - J.P. Morgan - Analyst
: Got an email question here, which is could we get some clarity on the partnership with Shionogi and its updates around the -- MDD and PPD
partnership in Asia?
Question: Anupam Rama - J.P. Morgan - Analyst
: Questions from the audience, Alana.
Unidentified Participant
Thank you. Very nice presentation. Can you tell me a little bit about the process of deciding to move from indications like essential tremor to an
indication that's a behavioral change because it seems like a pretty big move. Although I'm suspecting that you actually have lots of data and
reasons to choose that new, those indications for new focus.
Question: Anupam Rama - J.P. Morgan - Analyst
: And then maybe you could talk a little bit about your disease awareness efforts. You've touched on them in the presentation. But that seems like
something that the more you do the bigger pull through you have on some of the scripts data that's coming in.
Question: Anupam Rama - J.P. Morgan - Analyst
: Got another email question here, which is some of the questions from the mom's online forums center around. Is there ZURZUVAE safe or not safe
for breastfeeding mothers? Any commentary on that?
Question: Anupam Rama - J.P. Morgan - Analyst
: All right, what is the time to script look like? You get diagnosed and OB/GYN says, okay, here we need to move on to what's the time to script and
like where you were just saying, it's a 14 day course treatment. So many, many, many companies, go through some sort of 1Q seasonality on
reauthorizations and things like that. But this is just a 14 day treatment. How do we think about that, like 1Q seasonality?
Question: Anupam Rama - J.P. Morgan - Analyst
: 1Q seasonality.
Question: Anupam Rama - J.P. Morgan - Analyst
: Any final questions from the audience? All right. Thanks, Barry, and team.
| 
